Encorafenib Triplet Elicits Antitumor Activity in BRAF V600E+ mCRC
Encorafenib plus cetuximab, along with chemotherapy, was linked to antitumor activity and a manageable safety profile in patients with BRAF V600E-mutant metastatic colorectal cancer.
Auricular Acupuncture Offers Complimentary Approach to Manage Cancer Pain
Heather Jackson, PhD, FNP-BC, NEA-BC, FAANP, provides a case-based perspective on the benefit of auricular acupuncture as a tool for managing cancer pain.
Trifluridine/Tipiracil Plus Bevacizumab Improves OS in Refractory Metastatic Colorectal Cancer
Findings from the phase 3 SUNLIGHT study showed that adding bevacizumab to trifluridine/tipiracil boosted overall survival in metastatic colorectal cancer.
Frontline Liposomal Irinotecan/NALIRIFOX Confers OS Benefit in Metastatic Pancreatic Ductal Adenocarcinoma
The median overall survival with frontline liposomal irinotecan/NALIRIFOX was 11.1 months vs 9.2 months with nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
CheckMate 648 Update Showcases Long-Term Survival Benefit With Frontline Nivolumab in ESCC
The median overall survival with nivolumab plus chemotherapy was 12.8 months, vs 10.7 months with chemotherapy alone, in patients with treatment-naïve advanced esophageal squamous cell carcinoma.
Zolbetuximab Plus mFOLFOX6 Extends Survival for Patients with CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma
For patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma, treatment with zolbetuximab/mFOLFOX6 yielded a progression-free survival (PFS) of 10.61 months whereas placebo/mFOLFOX6 resulted in a PFS of 8.67 months.
Firstline Nivolumab/Chemotherapy Continues To Outperform Chemotherapy Alone for Advanced Gastric/GEJ/Esophageal Cancer At 3-Year Follow-Up
In an all-randomized population of patients with advanced gastric cancer, gastroesophageal junction, or esophageal adenocarcinoma, adding nivolumab to chemotherapy yielded a 21% reduction in the risk of death.
ASCO Guidelines Provide Road Map for Cancer Pain Management With Opioids
The American Society of Clinical Oncology (ASCO) has updated its guidelines providing recommendations for the management of cancer pain with opioids.
Frontline Zanubrutinib/Rituximab, Short-Course R-DHAOx Elicits Preliminary Results in Mantle Cell Lymphoma
Among 17 patients with mantle cell lymphoma, the complete remission rate with first-line treatment with zanubrutinib plus rituximab followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin was 88.2%.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Triplet Regimen of COM701, BMS-986207, and Nivolumab Shows Antitumor Activity in Platinum-Resistant Ovarian Cancer
Patients with heavily pretreated, platinum-resistant ovarian cancer showed promising responses with a triplet regimen consisting of COM701, BMS-986207, and nivolumab.
Optimizing Frailty Tools Are A Vital Component of Improving Care Across Hematologic Malignancies
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP, discusses key data of interest from the 2022 American Society of Hematology Meeting.
ASCO Guidelines Shine Light on Treatments for Gastroesophageal Cancer
The American Society of Clinical Oncology (ASCO) has released new guidelines providing recommendations for the optimal treatment of patients with advanced gastroesophageal cancer.
Low-Dose Nivolumab Plus Chemotherapy an Accessible Alternative to Full-Dose Checkpoint Inhibitors in Head and Neck Cancer
For patients with head and neck cancer who cannot access full-dose checkpoint inhibitors, adding low-dose nivolumab to metronomic chemotherapy may represent an acceptable alternative treatment approach.
Emerging Data Showcases Promising Advancements for Patients With HER2-Low Breast Cancer
Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP, reflects on data presented at the San Antonio Breast Cancer Symposium.
Sacituzumab Govitecan Continues to Prolong Survival in Patients With HR+/HER2– Breast Cancer
Patients with hormone receptor–positive, HER2-negative metastatic breast cancer derived benefit with sacituzumab govitecan regardless of Trop-2 expression.
POSITIVE Study Findings Shift Conversations on Pregnancy in ER+ Breast Cancer
Jamie Carroll, APRN, CNP, MSN, weighs in on how findings from the POSITIVE study may change dialogue surrounding pregnancy for women with estrogen receptor–positive breast cancer who wish to pause adjuvant therapy.
Frontline Pola-R-CHP, CAR-T Second-Line Therapy Are Not Cost-Effective Choices For Patients With DLBCL
An economic analysis showed that neither polatuzumab vedotin nor CD19-directed CAR T-cell therapy are likely to be the most cost-effective for patients with diffuse large B-cell lymphoma based on their high costs and current long-term survival estimates.
Rucaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer
Maintenance therapy with rucaparib monotherapy improved progression-free survival compared with placebo. However, the treatment also significantly elevated anemia and neutropenia rates in this setting.
Caressa Valdueza Highlights Best Practices for the Management of Common Adverse Events in Melanoma
Caressa Valdueza, MSN, AGNP-BC, AOCNP, discusses toxicity management with unfolding treatment options in melanoma.
Real-World Data Show Neoadjuvant Pertuzumab/Trastuzumab Increases pCR Rates in HER2+ Breast Cancer
Neoadjuvant pertuzumab/trastuzumab increased the rate of pathological complete response in patients with HER2-positive breast cancer.
Survivorship Clinic Visits Hold Answer to Questions About Post-Cancer Pregnancies
Ellen Miller, MSN, FNP-BC, a nurse practitioner who specializes in survivorship care, underscores what conversations surrounding fertility and pregnancy may look like after radiation.
Chemotherapy Plus Endocrine Therapy Increases Cognitive Impairment in Breast Cancer
Patients with breast cancer may be at risk for more intense cognitive impairment following treatment with chemotherapy plus endocrine therapy.
Second-Line Liso-Cel Continues to Improve Event-Free Survival in Large B-Cell Lymphoma
In the second line setting, lisocabtagene maraleucel (liso-cel; Breyanzi) significantly reduced the risk of an event for patients with high-risk relapsed/refractory large B-cell lymphoma, compared with standard-of-care chemoimmunotherapy induction.
Camizestrant Emerges As A Potentially Effective Oral SERD for Patients With HER2-Negative Advanced Breast Cancer
Camizestrant doubled progression-free survival compared with fulvestrant in patients with estrogen receptor–positive, HER2-negative advanced breast cancer.
Adjuvant T-DM1 With Concurrent Radiotherapy Is Not Associated with Cardiotoxic Concerns in Early-Stage HER2+ Breast Cancer
Patients with early-stage, HER2-positive breast cancer who received both adjuvant ado-trastuzumab emtansine and concurrent radiotherapy did not experience a significant drop in ejection fraction or global longitudinal strain.
Black Mulberry Extract Shows Efficacy in Oral Mucositis Management for Patients Receiving Chemotherapy
Black mulberry extract may help patients manage oral mucositis, dry mouth, and weight gain, while receiving oral cancer medications.
Label Update for Capecitabine Expands and Updates Indications
The FDA has approved updated labeling for capecitabine under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for certain older oncology drugs.
Capivasertib/Fulvestrant Boosts Progression-Free Survival in HR+/HER2– Breast Cancer
Capivasertib plus fulvestrant improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.
Caring for a Patient With Relapsed Mantle Cell Lymphoma Undergoing CAR T-Cell Therapy
CAR T-cell therapy represents a viable treatment option for many patients,
but there are potentially serious adverse events.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512